India markets closed
  • BSE SENSEX

    48,949.76
    +272.21 (+0.56%)
     
  • Nifty 50

    14,724.80
    +106.95 (+0.73%)
     
  • Dow

    34,398.01
    +167.67 (+0.49%)
     
  • Nasdaq

    13,555.88
    -26.54 (-0.20%)
     
  • BTC-INR

    4,197,373.50
    -8,083.00 (-0.19%)
     
  • CMC Crypto 200

    1,479.82
    +8.40 (+0.57%)
     
  • Hang Seng

    28,637.46
    +219.46 (+0.77%)
     
  • Nikkei

    29,331.37
    +518.77 (+1.80%)
     
  • EUR/INR

    88.8310
    +0.2007 (+0.23%)
     
  • GBP/INR

    102.2367
    -0.4033 (-0.39%)
     
  • AED/INR

    20.0100
    -0.0410 (-0.20%)
     
  • INR/JPY

    1.4787
    +0.0023 (+0.16%)
     
  • SGD/INR

    55.2280
    -0.0440 (-0.08%)
     

Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
Adicet Bio
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.

Details of the event are as follows:

Panel:

Gamma Delta CART-Cells, and “Squeezed” T-cells

Date:

Thursday, April 15, 2021

Time:

1:00 – 1:55 PM ET

Format:

Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com